Search Within

Sergio Andres Giralt

  1. "Karthik Nath"
Formats
  1. Meeting Abstract (13)
  2. Journal Article (8)
  3. Correspondence (1)
Groups
  1. Bone Marrow Transplant (22)
  2. CTCR Scholars (22)
  3. Center for Hematologic Malignancies (22)
  4. Department of Medicine (22)
  5. GME, Medicine (22)
  6. Graduate Medical Education (22)

More Groups

People
  1. Karthik Nath (22)
  2. Gunjan Shah (20)
  3. Michael Scordo (18)
  4. Sean Devlin (14)
  5. Alexander Lesokhin (11)
  6. Miguel-Angel Perales (11)

More People

Years
  1. 2025 (1)
  2. 2024 (5)
  3. 2023 (8)
  4. 2022 (8)
Publications
  1. Blood (8)
  2. Clinical Lymphoma, Myeloma and Leukemia (4)
  3. Transplantation and Cellular Therapy (3)
  4. Blood Cancer Journal (2)
  5. American Journal of Hematology (1)
  6. Bone Marrow Transplantation (1)

More Publications

Publishers
  1. American Society of Hematology (8)
  2. Elsevier Inc. (7)
  3. Nature Publishing Group (3)
  4. Ferrata Storti Foundation (1)
  5. John Wiley & Sons, Inc. (1)
  6. Massachusetts Medical Society (1)

More Publishers

Results (22)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy
    Journal Article

    Boardman, A. P.; Gutgarts, V.; Flynn, J. R.; Devlin, S. M.; Goldman, A.; Tomas, A. A.; Fein, J. A.; Slingerland, J. B.; Parascondola, A.; Lin, R. J.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • Infectious complications during treatment with commercial CAR T-cell therapy and bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E. M.; Shekarkhand, T.; Farzana, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R. S.; Nishimura, N.; Miller, K.; Costa, B. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Incidence and clinical impact of acute kidney injury: A comparison of CAR T-cell and bispecific antibody therapies
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B.; Farzana, T.; Jurgens, E.; Firestone, R.; Nath, K.; Chung, D.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
    Journal Article

    Nath, K.; Shekarkhand, T.; Nemirovsky, D.; Derkach, A.; Costa, B. A.; Nishimura, N.; Farzana, T.; Rueda, C.; Chung, D. J.; Landau, H. J.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma
    Journal Article

    Costa, B. A.; Flynn, J.; Nishimura, N.; Devlin, S. M.; Farzana, T.; Rajeeve, S.; Chung, D. J.; Landau, H. J.; Lahoud, O. B.; Scordo, M.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Reduced-intensity compared to nonmyeloablative conditioning in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic stem cell transplantation
    Journal Article

    Nath, K.; Peterson, K.; Brown, S.; Devlin, S.; Rodriguez, N.; Barker, J.; Giralt, S.; Gyurkocza, B.; Jakubowski, A.; Papadopoulos, E.; more...
    Transplantation and Cellular Therapy (2024)

    Fulltext@MSK | Save
  • Comparison of bendamustine versus fludarabine/cyclophosphamide lymphodepletion in adult patients receiving CD19 CAR-T cell therapy
    Meeting Abstract

    Landego, I.; Nemirovsky, D.; Devlin, S. M.; Wills, B.; Parascondola, A.; Saldia, A.; Dahi, P. B.; Tomas, A. A.; Ip, A.; Suh, H. C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A comparative analysis of infectious complications in patients with multiple myeloma treated with BCMA-targeted bispecific antibodies and CAR T-cell therapy
    Meeting Abstract

    Nath, K.; Shekarkhand, T.; Costa, B. A.; Nemirovsky, D.; Derkach, A.; Nishimura, N.; Farzana, T.; Rueda, C.; Chung, D.; Landau, H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A reproducible inflammatory biomarker signature identifies non-Hodgkin lymphoma patients at high risk of CAR-T treatment failure across different cohorts
    Meeting Abstract

    Raj, S.; Perales, M. A.; Fei, T.; Fein, J.; Tomas, A. A.; De LaPuerta, M. C.; Dahi, P.; Danylesko, I.; Epstein-Peterson, Z.; Fried, S.; more...
    Bone Marrow Transplantation (2023)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Nath, K.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save